Resolution Therapeutics Announces a £10m Extended Series A …

London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease. ... This …

CouponFollow Extension

£10
OFF

Resolution Therapeutics Announces A £10m Extended Series A …

6 days from now

London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease. ... This …

resolution-tx.com

£10
OFF

Resolution Therapeutics Announces A £10m Extended Series A

6 days from now

Apr 5, 2022 · Broadening research pipeline into allogeneic macrophages for the treatment of liver disease - London, 5 April, 2022 – Resolution Therapeutics Limited (“Resolution”), a …

synconaltd.com

£10
OFF

Resolution Therapeutics Announces £10m Boost… - Edinburgh …

6 days from now

The £10 million investment extends Series A financing of £26.6 million from Syncona, a specialist healthcare investment company, that was announced at the launch of Resolution in December …

ed.ac.uk

£10
OFF

News - Resolution Therapeutics

6 days from now

Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd. London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to …

resolution-tx.com

$13
OFF

Resolution Pads Series A, Adds Allogeneic Macrophage Cell Therapy ...

6 days from now

Apr 6, 2022 · Syncona Ltd. has added £10 million (US$13.1 million) to the £26.6 million it put into the series A round of Resolution Therapeutics Ltd., enabling the company to advance an …

bioworld.com

£10
OFF

Resolution Therapeutics Announces £10m Boost And New …

6 days from now

The £10 million investment extends Series A financing of £26.6 million from Syncona, a specialist healthcare investment company, that was announced at the launch of Resolution in December …

edinburghbioquarter.com

$13076904
OFF

Series A - Resolution Therapeutics - 2022-04-05 - Crunchbase

6 days from now

Apr 5, 2022 · Resolution Therapeutics raised $13076904 on 2022-04-05 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...

crunchbase.com

£10
OFF

Syncona : Resolution Therapeutics Announces A £10m Extended …

6 days from now

London, 5 April, 2022 - Resolution Therapeutics Limited ("Resolution"), a biopharmaceutical company developing macrophage cell therapy to treat advanced liver disease, today …

marketscreener.com

£10
OFF

Resolution Therapeutics Announces A £10M Extended Series A …

6 days from now

London, 5 April, 2022 - Resolution Therapeutics Limited ("Resolution"), a biopharmaceutical company developing macrophage cell therapy to treat advanced liver disease, today …

firstwordpharma.com

£26
OFF

Resolution Therapeutics Announces A £26.6m Series A ... - Syncona

6 days from now

May 6, 2024 · Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening …

synconaltd.com

£10
OFF

Resolution Therapeutics - Edinburgh Innovations

6 days from now

In 2022 Resolution Therapeutics completed a £10 million financing extension from Syncona. The extended Series A funding will allow Resolution to continue to develop its autologous …

ed.ac.uk

$83
OFF

Resolution Therapeutics Secures $83M To Advance Liver Therapy

6 days from now

Oct 3, 2024 · Resolution Therapeutics was co-founded by Syncona, a UK-based investment trust focused on helping to found, fund and progress healthcare companies, in 2020 after a two …

biopharma-reporter.com

FAQs about Resolution Therapeutics Announces a £10m Extended Series A … Coupon?

What's new at resolution Therapeutics?

Edinburgh Innovations | Resolution Therapeutics announces £10m boost… Resolution Therapeutics, a biopharmaceutical spinout company developing macrophage cell therapy to treat advanced liver disease, has completed a £10 million financing extension from Syncona and announced a new collaboration with biotech firm panCELLa. ...

Why did resolution Therapeutics get a series A funding extension?

Resolution Therapeutics received a £10 million financing extension in 2022 from Syncona for its Series A funding. This extended funding will enable Resolution to continue developing its autologous macrophage cell therapies and broaden its research activity into the development of an allogeneic platform to produce "off-the-shelf" macrophage cell therapies. ...

What does the extended series A funding mean for resolution?

The extended Series A funding will allow Resolution to continue to develop its autologous macrophage cell therapies alongside broadening its research activity into the development of an allogeneic platform to produce “off-the-shelf” macrophage cell therapies. ...

Is Resolution a company owned by Syncona?

London, 5 April 2022 – Resolution Therapeutics Limited (a biopharmaceutical company owned by Syncona Ltd, named as Syncona in the passage) is developing macrophage cell therapy to treat advanced liver disease. Today, they announced the completion of a £10m extension to the Series A financing from Syncona. ...

What does Series A funding mean for Resolution?

This extended Series A funding for Resolution will enable the company to continue to develop its autologous macrophage cell therapies and broaden its research activity into the development of an allogeneic platform to produce ‘off-the-shelf’ macrophage cell therapies. ...

What is Resolution TX?

Resolution is a company that discovers, develops, and takes to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com Syncona (LON: SYNC) is a healthcare company focused on founding, building and funding a portfolio of global leaders in life science. ...